INAB Stock Rating Reiterated, $6 Target Set on Trial Data

H.C. Wainwright has reiterated their rating on IN8bio (INAB) with a price target of $6, citing data from ongoing trials. This target indicates a potential upside based on the outcomes of the trial, which investors are closely monitoring. The reiteration of the rating suggests confidence in the company's performance and potential market position. These developments may impact investor sentiment and trading volumes as the trial progresses.